OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.23 +0.01 (+4.28%) As of 05/29/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NWBO alerts:Sign Up Key Stats Today's Range$0.22▼$0.2450-Day Range$0.19▼$0.2652-Week Range$0.19▼$0.37Volume1.95 million shsAverage Volume3.75 million shsMarket Capitalization$376.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Northwest Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies. The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications. Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.AI Generated. May Contain Errors. Read More Northwest Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreNWBO MarketRank™: Northwest Biotherapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Northwest Biotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.24% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 7.26.Change versus previous monthShort interest in Northwest Biotherapeutics has recently increased by 0.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentNorthwest Biotherapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Northwest Biotherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.40% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by Institutions0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NWBO Stock News HeadlinesNorthwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Below 200-Day Moving Average - Time to Sell?May 30 at 2:44 AM | americanbankingnews.comNorthwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below 200 Day Moving Average - Here's WhyMay 22, 2026 | americanbankingnews.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.May 30 at 1:00 AM | Behind the Markets (Ad)Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine PlatformApril 30, 2026 | prnewswire.comNorthwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis ClinicApril 21, 2026 | prnewswire.comNorthwest Biotherapeutics expands authorized common stock capacityJanuary 3, 2026 | msn.comNorthwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK ...November 22, 2025 | finanznachrichten.deNorthwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK FacilityNovember 20, 2025 | prnewswire.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.23 at the beginning of the year. Since then, NWBO stock has decreased by 1.5% and is now trading at $0.2265. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) released its quarterly earnings data on Friday, November, 14th. The biotechnology company reported ($18.22) earnings per share for the quarter. The biotechnology company had revenue of $0.20 million for the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings11/14/2025Today5/30/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year Founded1998Profitability EPS (Trailing Twelve Months)($18.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.16 million Net Margins-2,931.73% Pretax Margin-2,967.60% Return on EquityN/A Return on Assets-79.26% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.38 million Price / Sales273.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-7.55Miscellaneous Outstanding Shares1,663,370,000Free Float1,623,449,000Market Cap$376.75 million OptionableNot Optionable Beta-0.74 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:NWBO) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredWhen SpaceX goes public your retirement pays the priceWhen SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...Reagan Gold Group | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
